BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31953833)

  • 1. Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding a New Group Eligible for Active Surveillance.
    Nowroozi MR; Ayati M; Amini E; Aghamiri SM; Momeni SA; Ohadian Moghadam S; Valizadeh F
    Urol J; 2020 Jun; 17(4):370-373. PubMed ID: 31953833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
    Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
    World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
    Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
    Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
    Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
    Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
    Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
    Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
    Cooperberg MR; Cowan JE; Lindquist KJ; Kobayashi Y; Simko JP; Bengtsson H; Singh K; Ngo V; Avila A; Newcomb LF; Tretriakova M; Lin DW; Stone S; Carroll PR; Paris PL
    Eur Urol; 2021 Jan; 79(1):141-149. PubMed ID: 33148472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
    Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
    Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
    Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
    Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
    Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
    Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
    Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy.
    Bianchi R; Cozzi G; Petralia G; Alessi S; Renne G; Bottero D; Brescia A; Cioffi A; Cordima G; Ferro M; Matei DV; Mazzoleni F; Musi G; Mistretta FA; Serino A; Tringali VML; Coman I; De Cobelli O
    Medicine (Baltimore); 2016 Oct; 95(40):e4519. PubMed ID: 27749525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
    Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
    Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
    BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
    Jeon HG; Yoo JH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM; Ferrari M; Brooks JD; Chung BI
    PLoS One; 2017; 12(11):e0186026. PubMed ID: 29136019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
    Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
    Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
    Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.